ReviewCurrent pharmaceutical design2017
Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases.
Review in Current pharmaceutical design, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04395547 (A Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Safety and Efficacy of JointAlive™ on Improving Knee Joint Function in Adults With Mild to Moderate Knee Osteoarthritis), which is not on this map. Cited by 114 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Safety and Efficacy of JointAlive™ on Improving Knee Joint Function in Adults With Mild to Moderate Knee Osteoarthritis
Who cites it
114 citing papers in PubMed, 2 syntheses or guidelines pooled it, 243 citations in OpenAlex.
- Commercial Chinese polyherbal preparation Zao Ren An Shen prescription for primary insomnia: a systematic review with meta-analysis and trial sequential analysis.Frontiers in pharmacology · 2024Pooled it
- The efficacy and potential pharmacological mechanism of Fufang Danshen Tablet in promoting the rehabilitation of ischemic stroke: a meta-analysis andFrontiers in neurologyPooled it
- The endophyte secondary metabolite phenazine-1-carboxylic acid promotes tanshinone biosynthesis in Salvia miltiorrhiza callus.Journal of natural medicines · 2026Article
- Fertility matters: linking male sterility to starch synthesis in Salvia miltiorrhiza.Plant physiology · 2026Article
- Multi-omics elucidation of temporal patterns in tanshinone accumulation in Salvia miltiorrhiza.BMC plant biology · 2026Article
- Cardiovascular Benefits ofFood science & nutrition · 2026Review
- Article
- Recent Advances in Transcription Factor-Mediated Regulation of Salvianolic Acid Biosynthesis inPlants (Basel, Switzerland) · 2026Review
- Therapeutic functions of tanshinone IIA in a zebrafish model of glucocorticoid-induced osteoporosis.Frontiers in pharmacology · 2026Article
- Comprehensive overview of alternative medicine in the treatment of ankylosing spondylitis: Symptoms, pathogenesis, diagnosis and treatments (Review).Biomedical reports · 2026Review
- SmbZIP5 Integrates Abscisic and Jasmonic Acid Signalling to Positively Regulate Tanshinone Biosynthesis in Salvia miltiorrhiza.Plant biotechnology journal · 2025Article
- Therapeutic potential and mechanisms of traditional Chinese medicine in regulating energy metabolism imbalance in heart failure.Chinese herbal medicines · 2025Review
- Tanshinone IIA suppresses the proliferation and fibrosis of mesangial cell in diabetic nephropathy though WTAP-mediated mScientific reports · 2025Article
- Exploring the Therapeutic Potential ofJournal of clinical medicine · 2025Review
- NLRP3 Inflammasome-Mediated Pyroptosis in Diabetic Nephropathy: Pathogenic Mechanisms and Therapeutic Targets.Journal of inflammation research · 2025Review
- Effects of monocropping soil on plant growth and rhizosphere microbial community structure ofPeerJ · 2025Article
- Targeting microglia polarization with Chinese herb-derived natural compounds for neuroprotection in ischemic stroke.Frontiers in cell and developmental biology · 2025Review
- Advances in the structural characterization and pharmacological activity of Salvia miltiorrhiza polysaccharides.Frontiers in chemistry · 2025Review
- The efficacy and safety of herbal formulas for adults with pulmonary hypertension combined with chronic obstructive pulmonary disease: a systematic review and meta-analysis involving 1,865 participants.Journal of thoracic disease · 2024Article
- Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salvia miltiorrhiza Bunge, also known as Danshen in Chinese, has been widely used to treat cardiovascular diseases (CVD) in China and other Asia countries. Here, we summarize literatures of the historical traditional Chinese medicine (TCM) interpretation of the action of Salvia miltiorrhiza, its use in current clinical trials, its main phytochemical constituents and its pharmacological findings by consulting Pubmed, China Knowledge Resource Integrated, China Science and Technology Journal, and the Web of Science Databases. Since 2000, 39 clinical trials have been identified that used S. miltiorrhiza in TCM prescriptions alone or with other herbs for the treatment of patients with CVD. More than 200 individual compounds have been isolated and characterized from S. miltiorrhiza, which exhibited various pharmacological activities targeting different pathways for the treatment of CVD in various animal and cell models. The isolated compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-CVD drugs. Meanwhile, there are also some rising concerns of the potential side effects and drug-drug interactions of this plant. The insights gained from this study will help us to better understanding of the actions of this herb for management of cardiovascular disorders. As an herb of red root, S. miltiorrhiza will act as a potential red light to prevent the development of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.